Skip to content
Operation Infinite Justice – Lifestyle
Author:
MBX Biosciences, Inc.
MBX Biosciences to Host Virtual Investor Event to Discuss Once-Weekly Canvuparatide Presentations at ENDO 2026
June 1, 2026
MBX Biosciences to Present at the Jefferies 2026 Global Healthcare Conference in New York City
May 26, 2026
MBX Biosciences Provides Obesity Portfolio Update Including Initial Phase 1 Data for MBX 4291 Supporting Potential for Once-Monthly Dosing
May 11, 2026
MBX Biosciences Reports First Quarter 2026 Financial Results and Corporate Highlights
May 7, 2026
MBX Biosciences Announces Appointment of Mark Soued as Chief Commercial Officer and Inducement Grant Award
May 7, 2026
MBX Biosciences to Host In-Person and Virtual Obesity Day on May 11, 2026 to Discuss Expanding Obesity Portfolio
April 23, 2026
MBX Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 3, 2026
MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism
March 26, 2026
MBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights
March 12, 2026
MBX Biosciences Appoints Karen Basbaum as Chief Business Officer
March 10, 2026
1
2
Next Page
→